NCT00087490

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,077 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

Conditions

• Skin/Soft Tissue Infections
• Methicillin Resistant Staphylococcus Aureus (MRSA)

Interventions

Type	Name	Description
DRUG	linezolid
DRUG	vancomycin

Timeline

• Start date: 2004-10-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2004-07-13
• Last updated: 2012-08-08
• Results posted: 2012-08-08

Locations

126 sites across 16 countries: United States, Argentina, Belgium, Brazil, Chile, Colombia, Italy, Malaysia, Mexico, Portugal, Russia, Singapore, South Africa, Spain, United Kingdom, Venezuela